乳酸作为临床肿瘤生物标志物:胶质母细胞瘤MR波谱成像中乳酸检测与定量的优化
研究纳入27例胶质母细胞瘤患者,比较标准后处理软件与本中心改良技术对中等回波时间MRS中乳酸与脂质信号的分离效果。经体模校准后,改良技术使乳酸Cramér-Rao下界从18%降至8%,单例中标准分析因脂质污染无法检出乳酸而改良技术可检出,正常表现白质中未检出乳酸。作者认为该方法有望提高乳酸信号分析可靠性并推动其成为脑肿瘤临床常规生物标志物。
要点
- 改良后处理技术使乳酸Cramér-Rao下界由18%降至8%,提升乳酸信号质量。
- 1例中标准分析因脂质污染无法检出乳酸,仅改良技术可检出。
- 改良分析所得体内乳酸中位数4.77 mmol/l(范围1.5-9.2),正常表现白质中未检出乳酸。
关键影像表现/征象
- 基于离体校准,体内MR波谱测量分析使%CR(Lac)从18%改善至8%。
- 单例中标准分析因乳酸信号被脂质污染而无法检出乳酸,仅改良技术可实现检出。
- 改良分析所得体内乳酸值中位数4.77 mmol/l(范围1.5-9.2),正常表现白质中未检出乳酸。
诊断标准与关键数值
- 以Cramér-Rao下界(%CR)作为评价MRS后处理结果质量的主要标准,改良技术使%CR(Lac)从18%降至8%。
- 改良分析所得体内乳酸值中位数4.77 mmol/l(范围1.5-9.2),正常表现白质中未检出乳酸,支持乳酸作为胶质母细胞瘤区域异质性的生物标志物。
临床应用与阅片要点
- 在中等回波时间MRS采集后处理中,采用改良技术可分离乳酸与脂质信号,提高乳酸检出可靠性。
- 报告乳酸浓度时需注意脂质污染可导致标准分析假阴性,单例中标准分析未检出而改良技术检出。
- 正常表现白质中未检出乳酸,可作为参考基线。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Increased lactate (Lac) level in brain tumours is in vivo detectable by 1H MR spectroscopy (MRS) but is frequently overlapped by strong lipid signals, which either leads to a weak quality of the Lac signal or even inhibit its detection. We sought to optimize the separation of Lac from lipid signals in intermediate-echo time MRS acquisitions thus allowing its applicability as clinical biomarker in glioblastomas.
METHODS: Data of 27 patients with glioblastoma multiforme (GBM) were analysed using standard post-processing software as well as in-house modified technique based on the same commercially available software. The patients' Lac concentration values provided by the MRS post-processing technique were converted to realistic concentrations by using an appropriately calibrated phantom. The Cramér-Rao lower bound (%CR) was the principal criterion for estimating the quality of the MRS post-processing results.
RESULTS: Based on the ex vivo calibration, the analysis of the in vivo MR spectroscopy measurements led to an improvement of the %CR(Lac) value from 18 % to 8 %. In a single case, the detection of Lac was achievable only by the modified technique, as Lac signal was contaminated with lipids using the standard analysis. The resulting in vivo Lac values from the modified analysis (median: 4.77 mmol/l, range: 1.5-9.2) were considered as a realistic order of magnitude for the metabolite concentrations, whereas no Lac was identified in the normal appearing white matter. This qualified also Lac mapping as a biomarker for regional heterogeneity in GBM.
CONCLUSIONS: The proposed methodology is a promising first step for more reliable analysis of Lac signal, decontaminating it from lipid peaks in MRS, and may help to establish Lac as a biomarker for brain tumours in clinical routine.
引用
- Bisdas S, Schäfer R, Kolb R, et al. Lactate as clinical tumour biomarker: Optimization of lactate detection and quantification in MR spectroscopic imaging of glioblastomas. Eur J Radiol. 2020. PMID: 32668356. doi:10.1016/j.ejrad.2020.109171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。